Portal de investigación
Brigatinib inALK-positive non-small cell lung cancer: real-world data in the Latin American population (Bri-world extend CLICaP)
Autores organización
Autores
- Heredia, D
- Barrón, F
- Campos, S
- Rodriguez-Cid, J
- Martinez-Barrera, L
- Alatorre, J
- Salinas, MA
- Lara-Mejia, L
- Flores-Estrada, D
- Arrieta, O
Grupos de investigación
Resumen
Background:Brigatinib has demonstrated its efficacy as first-line therapy and in further lines forALK-positive non-small cell lung cancer (NSCLC) patients; however, real-world data in Latin America are scarce.Methods:From January 2018 to March 2020, 46 patients with advancedALK-positive NSCLC received brigatinib as second or further line of therapy in Mexico and Colombia. The primary endpoint was progression-free survival (PFS); secondary endpoint was time to treatment discontinuation (TTD).Results:At a median follow-up of 9.3 months, the median PFS was 15.2 months (95% CI: 11.6-18.8), and TTD was 18.46 months (95% CI: 9.54-27.38). The estimated overall survival at 12 months was 80%. Safety profile was consistent with previously published data.Conclusion:Brigatinib is an effective treatment for previously treatedALK-positive NSCLC patients in a real-world setting.
Datos de la publicación
- ISSN/ISSNe:
- 1479-6694, 1744-8301
- Tipo:
- Article
- Páginas:
- 169-181
- Enlace a otro recurso:
- www.scopus.com
Future Oncology FUTURE MEDICINE LTD
Citas Recibidas en Web of Science: 4
Citas Recibidas en Scopus: 7
Documentos
- No hay documentos
Filiaciones
Keywords
- anaplastic lymphoma kinase; brigatinib; ceritinib; crizotinib; early access; lung cancer; non-small cell lung cancer; real-world evidence
Proyectos asociados
EVALUACIÓN IN VITRO DEL PERFIL DE CITOCINAS Y FENOTIPO INDUCIDO POR ESPECIES DE Streptococcus ORALES EN CÉLULAS DENDRÍTICAS CONDICIONADAS POR QUERATINOCITOS GINGIVALES
Investigador Principal: ANDRES FELIPE CARDONA MENDOZA
PCI-2018-10200 . 2019
Determinación de la huella transcipcional de mastocitos aislados de pulpa dental humana sana y con signos clínicos de inflamación
Investigador Principal: MARIA ROSA BUENAHORA TOBAR
PCI-2019-10765 . 2020
Citar la publicación
Heredia D,Barrón F,Cardona AF,Campos S,Rodriguez J,Martinez L,Alatorre J,Salinas MA,Lara L,Flores D,Arrieta O. Brigatinib in<i>ALK</i>-positive non-small cell lung cancer: real-world data in the Latin American population (Bri-world extend CLICaP). Future Oncol. 2020. 17. (2):p. 169-181. IF:3,404. (3).